JP2013520507A - Ｃ型肝炎の処置のためのピラゾロピリダジン誘導体 - Google Patents

Ｃ型肝炎の処置のためのピラゾロピリダジン誘導体 Download PDF

Info

Publication number
JP2013520507A
JP2013520507A JP2012555088A JP2012555088A JP2013520507A JP 2013520507 A JP2013520507 A JP 2013520507A JP 2012555088 A JP2012555088 A JP 2012555088A JP 2012555088 A JP2012555088 A JP 2012555088A JP 2013520507 A JP2013520507 A JP 2013520507A
Authority
JP
Japan
Prior art keywords
alkyl
phenyl
hydrogen
substituted
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2012555088A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013520507A5 (enExample
Inventor
ジョン・エフ・カドウ
リチャード・プラシット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2013520507A publication Critical patent/JP2013520507A/ja
Publication of JP2013520507A5 publication Critical patent/JP2013520507A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2012555088A 2010-02-25 2011-02-23 Ｃ型肝炎の処置のためのピラゾロピリダジン誘導体 Ceased JP2013520507A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30808410P 2010-02-25 2010-02-25
US61/308,084 2010-02-25
PCT/US2011/025803 WO2011106340A1 (en) 2010-02-25 2011-02-23 Pyrazolopyridazine derivatives for the treatment of hepatitis c

Publications (2)

Publication Number Publication Date
JP2013520507A true JP2013520507A (ja) 2013-06-06
JP2013520507A5 JP2013520507A5 (enExample) 2014-04-10

Family

ID=43797530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012555088A Ceased JP2013520507A (ja) 2010-02-25 2011-02-23 Ｃ型肝炎の処置のためのピラゾロピリダジン誘導体

Country Status (8)

Country Link
US (1) US8324212B2 (enExample)
EP (1) EP2539340B1 (enExample)
JP (1) JP2013520507A (enExample)
KR (1) KR20130008570A (enExample)
CN (1) CN102858777B (enExample)
AU (1) AU2011220915A1 (enExample)
MX (1) MX2012009759A (enExample)
WO (1) WO2011106340A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0818244A2 (pt) * 2007-10-24 2015-06-16 Merck Sharp & Dohme Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
US9303020B2 (en) 2012-02-08 2016-04-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006510736A (ja) * 2002-11-01 2006-03-30 バイロファーマ・インコーポレイテッド ベンゾフラン化合物、組成物およびｃ型肝炎感染症および関連疾患の治療または予防方法
JP2009520735A (ja) * 2005-12-22 2009-05-28 スミスクライン・ビーチャム・コーポレイション 抗ウイルス性２−カルボキシ−チオフェン化合物
WO2010030592A1 (en) * 2008-09-11 2010-03-18 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
WO2010030538A2 (en) * 2008-09-11 2010-03-18 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57123181A (en) 1981-01-23 1982-07-31 Mitsubishi Paper Mills Ltd Preparation of pyrazolo (1,5-a) pyridine derivative
US5917038A (en) 1996-11-22 1999-06-29 Eli Lilly And Company Process of preparing substituted acrylamides
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
JP2004525150A (ja) 2001-03-30 2004-08-19 スミスクライン ビーチャム コーポレーション 治療用化合物としてのピラゾロピリジン類の使用
EP1746888A2 (en) * 2004-05-13 2007-01-31 Viropharma Incorporated Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
GEP20105124B (en) * 2005-07-25 2010-11-25 Array Biopharma Inc Novel macrocyclic inhibitors of hepatitis c virus replication
GB0707000D0 (en) 2007-04-12 2007-05-30 Istituto Di Ricerche D Biolog Antiviral agents
CA2714254A1 (en) 2008-02-14 2009-08-20 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
WO2009137500A1 (en) 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2009137493A1 (en) 2008-05-05 2009-11-12 Wyeth 2-substituted benzofuran compounds to treat infection with hepatitis c virus
US7994171B2 (en) 2008-09-11 2011-08-09 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US20110031301A1 (en) 2009-08-06 2011-02-10 Segletes David S Joining of Electrical Generator Components
TW201138786A (en) 2010-02-19 2011-11-16 Glaxo Group Ltd Therapeutic compounds
AR080433A1 (es) 2010-03-02 2012-04-11 Merck Sharp & Dohme Derivados de benzofurancarboxamidas utiles para tratar o prevenir infecciones por vhc y composiciones farmaceuticas que los contienen.
WO2011106929A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006510736A (ja) * 2002-11-01 2006-03-30 バイロファーマ・インコーポレイテッド ベンゾフラン化合物、組成物およびｃ型肝炎感染症および関連疾患の治療または予防方法
JP2009520735A (ja) * 2005-12-22 2009-05-28 スミスクライン・ビーチャム・コーポレイション 抗ウイルス性２−カルボキシ−チオフェン化合物
WO2010030592A1 (en) * 2008-09-11 2010-03-18 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
WO2010030538A2 (en) * 2008-09-11 2010-03-18 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c

Also Published As

Publication number Publication date
AU2011220915A1 (en) 2012-10-11
KR20130008570A (ko) 2013-01-22
MX2012009759A (es) 2012-09-07
US20120046294A1 (en) 2012-02-23
US8324212B2 (en) 2012-12-04
EP2539340A1 (en) 2013-01-02
WO2011106340A1 (en) 2011-09-01
CN102858777A (zh) 2013-01-02
EP2539340B1 (en) 2014-08-27
CN102858777B (zh) 2015-01-07

Similar Documents

Publication Publication Date Title
EP2331502B1 (en) Compounds for the treatment of hepatitis c
EP2545050B1 (en) Compounds for the treatment of hepatitis c
JP5735551B2 (ja) Ｃ型肝炎の処置のための化合物
JP5343011B2 (ja) Ｃ型肝炎の治療のための化合物
JP2013520507A (ja) Ｃ型肝炎の処置のためのピラゾロピリダジン誘導体
US8445497B2 (en) Compounds for the treatment of hepatitis C
EP2812325B1 (en) Novel compounds for the treatment of hepatitis c
EP2276764B1 (en) Compounds for the treatment of hepatitis c
JP2018509401A (ja) Ｃ型肝炎の治療のための新規化合物
JP2016505011A (ja) Ｃ型肝炎の治療用の大環状ベンゾフランおよびアザベンゾフラン化合物
CN101980711B (zh) 芳族杂环稠合的吲哚并苯并二氮杂*hcv ns5b抑制剂
EP2831066A1 (en) Benzofuran derivatives for the treatment of hepatitis c
JP2017509700A (ja) Ｃ型肝炎治療用の含シアノアザベンゾフラン化合物
WO2016133970A1 (en) Benzofurans substituted with primary benzamide as hcv inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141216

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20141218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150227

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150728

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20151124